Updated: Lilly’s shares tank after trimming revenue guidance. It also cut three assets

Kyle LaHucik

Senior Reporter

Eli Lilly lowered the top end of its full-year revenue guidance by $600 million on Wednesday, as its third-quarter sales were about $800 million below …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Lilly’s shares tank after trimming revenue guidance. It also cut three assets

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Up­dat­ed: Lil­ly’s shares tank af­ter trim­ming rev­enue guid­ance. It al­so cut three as­sets

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Updated: Lilly’s shares tank after trimming revenue guidance. It also cut three assets